Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
Omeros (NASDAQ: OMER) has scheduled the release of its fourth quarter and year-end financial results for Monday, March 31, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss financial results and recent developments.
Investors can access the live webcast through Omeros' website at investor.omeros.com/upcoming-events. For phone participation, registration is required to receive a PIN. Participants can either dial in using the provided conference line and PIN or use the 'Call Me' option. A replay will be available at investor.omeros.com/archived-events.
Omeros (NASDAQ: OMER) ha programmato la pubblicazione dei risultati finanziari del quarto trimestre e dell'anno chiuso per lunedì 31 marzo 2025, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica e una diretta web alle 16:30 ora orientale (13:30 ora del Pacifico) per discutere i risultati finanziari e gli sviluppi recenti.
Gli investitori possono accedere alla diretta web tramite il sito di Omeros all'indirizzo investor.omeros.com/upcoming-events. Per partecipare telefonicamente, è necessaria la registrazione per ricevere un PIN. I partecipanti possono chiamare utilizzando la linea conferenza fornita e il PIN oppure utilizzare l'opzione 'Call Me'. Una registrazione sarà disponibile su investor.omeros.com/archived-events.
Omeros (NASDAQ: OMER) ha programado la publicación de sus resultados financieros del cuarto trimestre y del año para el lunes 31 de marzo de 2025, después del cierre del mercado. La compañía llevará a cabo una llamada de conferencia y una transmisión web a las 4:30 p.m. hora del Este (1:30 p.m. hora del Pacífico) para discutir los resultados financieros y los desarrollos recientes.
Los inversores pueden acceder a la transmisión en vivo a través del sitio web de Omeros en investor.omeros.com/upcoming-events. Para participar por teléfono, se requiere registro para recibir un PIN. Los participantes pueden marcar utilizando la línea de conferencia y el PIN proporcionados o utilizar la opción 'Call Me'. Una grabación estará disponible en investor.omeros.com/archived-events.
오메로스 (NASDAQ: OMER)는 2025년 3월 31일 월요일에 시장 마감 후 4분기 및 연간 재무 결과 발표를 예정하고 있습니다. 회사는 동부 표준시 오후 4시 30분 (태평양 표준시 오후 1시 30분)에 재무 결과 및 최근 개발 사항에 대해 논의하기 위한 전화 회의 및 웹캐스트를 개최할 것입니다.
투자자는 investor.omeros.com/upcoming-events에서 오메로스 웹사이트를 통해 실시간 웹캐스트에 접근할 수 있습니다. 전화 참여를 위해서는 PIN을 받기 위한 등록이 필요합니다. 참가자는 제공된 회의 전화와 PIN을 사용하여 전화하거나 'Call Me' 옵션을 사용할 수 있습니다. 재생은 investor.omeros.com/archived-events에서 제공됩니다.
Omeros (NASDAQ: OMER) a prévu la publication de ses résultats financiers du quatrième trimestre et de l'année pour le lundi 31 mars 2025, après la fermeture du marché. L'entreprise organisera une conférence téléphonique et un webinaire à 16h30 heure de l'Est (13h30 heure du Pacifique) pour discuter des résultats financiers et des développements récents.
Les investisseurs peuvent accéder au webinaire en direct via le site d'Omeros à l'adresse investor.omeros.com/upcoming-events. Pour participer par téléphone, une inscription est nécessaire pour recevoir un PIN. Les participants peuvent soit composer le numéro de la conférence fourni avec le PIN, soit utiliser l'option 'Call Me'. Un enregistrement sera disponible sur investor.omeros.com/archived-events.
Omeros (NASDAQ: OMER) hat die Veröffentlichung seiner Finanzzahlen für das vierte Quartal und das Jahresende für Montag, den 31. März 2025, nach Börsenschluss angesetzt. Das Unternehmen wird um 16:30 Uhr Eastern Time (13:30 Uhr Pacific Time) eine Telefonkonferenz und einen Webcast veranstalten, um die Finanzzahlen und aktuelle Entwicklungen zu besprechen.
Investoren können über die Website von Omeros unter investor.omeros.com/upcoming-events auf den Live-Webcast zugreifen. Für die telefonische Teilnahme ist eine Registrierung erforderlich, um eine PIN zu erhalten. Die Teilnehmer können entweder die bereitgestellte Konferenzleitung und die PIN wählen oder die Option 'Call Me' nutzen. Eine Aufzeichnung wird unter investor.omeros.com/archived-events verfügbar sein.
- None.
- None.
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2024, on Monday, March 31, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Conference Call Details
For online access to the live webcast of the conference call, go to Omeros’ website at https://investor.omeros.com/upcoming-events.
To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will have two options: (1) Dial in to the conference line provided at the registration site using the PIN provided to you, or (2) choose the “Call Me” option, which will instantly dial the phone number you provide. Should you lose your PIN or registration confirmation email, simply re-register to receive a new PIN.
A replay of the call will be made accessible online at https://investor.omeros.com/archived-events.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros’ long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 single- and multiple-ascending dose clinical studies. Zaltenibart, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing toward Phase 3 clinical trials for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros’ lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder. Omeros also is advancing a broad portfolio of novel cellular and molecular immuno-oncology programs. For more information about Omeros and its programs, visit www.omeros.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326800498/en/
Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations
IR@omeros.com
Source: Omeros Corporation
FAQ
When will Omeros (OMER) release Q4 and full-year 2024 earnings?
What time is the OMER Q4 2024 earnings conference call?
How can investors access Omeros (OMER) Q4 2024 earnings call?
Will there be a replay available for OMER's Q4 2024 earnings call?
